Glenmark Pharmaceuticals to Launch 8.4% Sodium Bicarbonate Injection
MT Newswires Live
Nov 04
Glenmark Pharmaceuticals Inc., USA, a unit of Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296), is poised to launch its 8.4% sodium bicarbonate injection and begin its distribution this month, according to a Tuesday filing to the Indian stock exchanges.
The injection is bioequivalent and therapeutically equivalent to Abbott Laboratories Pharmaceutical Products Division's reference listed drug, 8.4% Sodium Bicarbonate Injection.
As per IQVIA's sales data for the 12-month period ended August, the 8.4% Sodium Bicarbonate Injection recorded annual sales of around $63.8 million.
The company's shares were down nearly 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.